An overview of the mechanism of action of the monoclonal antibody vedolizumab

Journal of Crohn's and Colitis

Volumn 10, Issue 12, 2016, Pages 1437-1444

  Wyant, Tim ^a   Fedyk, Eric ^b   Abhyankar, Brihad ^c  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b Takeda Pharmaceuticals International Inc   (United States)

^c Takeda Global Research and Development Centre Europe   (United Kingdom)

Author keywords

Crohn's disease; Ulcerative colitis; Vedolizumab

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; TUMOR NECROSIS FACTOR; VEDOLIZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

BIOLOGICAL THERAPY; CELL INFILTRATION; CROHN DISEASE; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE MIGRATION; MUCOSA INFLAMMATION; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; ULCERATIVE COLITIS; ANIMAL; COLITIS, ULCERATIVE; DRUG EFFECTS; INTESTINE MUCOSA; LEUKOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; INTESTINAL MUCOSA; LEUKOCYTES;

EID: 85014807908     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw092     Document Type: Review

References (85)

1. Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis 2012;18:1-15
2. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008;14:390-400
3. Graham DB, Xavier RJ. From genetics of inflammatory bowel disease towards mechanistic insights. Trends Immunol 2013;34:371-8
4. Hanauer SB. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12[Suppl 1]:S3-9
5. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014;20:6-21
6. Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Ther Adv Gastroenterol 2010;3:239-58
7. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther Adv Gastroenterol 2015;8:66-82
8. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol 2014;7:6-19
9. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53[Suppl 5]:V1-16
10. McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 2012;4:883-98
11. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014;14:329-42
12. Lichtenstein GR. Comprehensive review: Antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Ther Adv Gastroenterol 2013;6:269-93
13. Peyrin-Biroulet L, Lemann M. Review article: Remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870-9
14. Akobeng AA, Sandborn WJ, Bickston SJ, et al. Tumor necrosis factoralpha antagonists twenty years later: What do Cochrane Reviews tell us? Inflamm Bowel Dis 2014;20:2132-41
15. Rogler G. Where are we heading to in pharmacological IBD therapy? Pharmacol Res 2015;100:220-7
16. Rosenfeld G, Parker CE, MacDonald JK, Bressler B. Etrolizumab for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2015;12:CD011661
17. Vermeire S, Sandborn WJ, Danese S, et al. Turandot: A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 [PF] in patients with moderate to severe ulcerative colitis [UC]. J Crohns Colitis 2015;9:S13
18. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Discov 2005;4:510-8
19. Davenport RJ, Munday JR. Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Discov Today 2007;12:569-76
20. FDA. Information on natalizumab. [Marketed as Tysabri.] 2015. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107198.htm Accessed February 18 2015
21. FDA. FDA approves entyvio to treat ulcerative colitis and Crohn's disease. 2014 http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm398065.htm Accessed September 1, 2015
22. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the α4β7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7
23. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N Engl J Med 2005;352:2499-507
24. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710
25. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21
26. Engelhardt B, RansohoffRM. The ins and outs of T-lymphocyte trafficking to the CNS: Anatomical sites and molecular mechanisms. Trends Immunol 2005;26:485-95
27. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol 2011;12:485-91
28. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007;8:215
29. Schweighoffer T, Tanaka Y, Tidswell M, et al. Selective expression of integrin α4β7 on a subset of human CD4+ memory T cells with hallmarks of gut-trophism. J Immunol 1993;151:717-29
30. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348:68-72
31. Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B, Butcher EC. Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo. J Immunol 1994;152:3282-93
32. DeNucci CC, Pagan AJ, Mitchell JS, Shimizu Y. Control of α4β7 integrin expression and CD4 T cell homing by the β1 integrin subunit. J Immunol 2010;184:2458-67
33. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75
34. Erle DJ, Briskin MJ, Butcher EC, et al. Expression and function of the MAdCAM-1 receptor, integrin α4β7, on human leukocytes. J Immunol 1994;153:517-28
35. Rott LS, Briskin MJ, Andrew DP, Berg EL, Butcher EC. A fundamental subdivision of circulating lymphocytes defined by adhesion to mucosal addressin cell adhesion molecule-1. Comparison with vascular cell adhesion molecule-1 and correlation with β7 integrins and memory differentiation. J Immunol 1996;156:3727-36
36. Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012;18:2107-19
37. Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs 2013;5:842-50
38. Gorfu G, Rivera-Nieves J, Ley K. Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med 2009;9:836-50
39. Kilshaw PJ. Alpha e beta 7. Mol Pathol 1999;52:203-7
40. Coisne C, Mao W, Engelhardt B. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 2009;182:5909-13
41. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
42. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25
43. Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 2006;65[Suppl 3]:iii48-53
44. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47
45. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol 2010;9:425-37
46. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Gastroenterology 1996;111:1373-80
47. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9
48. Yu Y, Zhu J, Mi LZ, et al. Structural specializations of α4β7, an integrin that mediates rolling adhesion. J Cell Biol 2012;196:131-46
49. Haanstra KG, Hofman SO, Lopes Estevao DM, et al. Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol 2013;190:1961-73
50. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumabassociated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
51. Brown DW, Furness J, Speight PM, et al. Mechanisms of binding of cutaneous lymphocyte-associated antigen-positive and αeβ7-positive lymphocytes to oral and skin keratinocytes. Immunology 1999;98:9-15
52. Erle DJ, Brown T, Christian D, Aris R. Lung epithelial lining fluid T cell subsets defined by distinct patterns of β7 and β1 integrin expression. Am J Respir Cell Mol Biol 1994;10:237-44
53. Jenkinson SE, Whawell SA, Swales BM, et al. The ae[CD103]β7 integrin interacts with oral and skin keratinocytes in an E-cadherin-independent manner. Immunology 2011;132:188-96
54. Pauls K, Schon M, Kubitza RC, et al. Role of integrin ae[CD103]β7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol 2001;117:569-75
55. Smyth LJ, Kirby JA, Cunningham AC. Role of the mucosal integrin ae[CD103]β7 in tissue-restricted cytotoxicity. Clin Exp Immunol 2007;149:162-70
56. Overstreet MG, Gaylo A, Angermann BR, et al. Inflammation-induced interstitial migration of effector CD4[+] T cells is dependent on integrin av. Nat Immunol 2013;14:949-58
57. Schwarzbauer JE, DeSimone DW. Fibronectins, their fibrillogenesis, and in vivo functions. Cold Spring Harb Perspect Biol 2011, July 1;3. doi: 10.1101/cshperspect.a005041
58. Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther 2015;42:188-202
59. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results. Gut 2015;64:77-83
60. Steffen BJ, Butcher EC, Engelhardt B. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am J Pathol 1994;145:189-201
61. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest 2010;120:1368-79
62. Allavena R, Noy S, Andrews M, Pullen N. CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis. Am J Pathol 2010;176:556-62
63. del Pilar Martin M, Cravens PD, Winger R, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008;65:1596-603
64. Stüve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006;63:1383-7
65. Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol 2013;264:123-6
66. D'Haens G, Vermeire S, Cataldi F, et al. Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study. J Crohns Colitis 2014;Suppl 1:S4-5
67. Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1691-9
68. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-27 e3
69. Biogen. Us-Tysabri-update. June 2015 edn. Weston, USA: MedInfo: Biogen, 2015
70. Sands B, Cohen R, Isaacs K, et al. Infusion-related reactions with vedolizumab treatment in patients with UC or CD during the GEMINI 1 AND GEMINI 2 clinical trials. J Crohns Colitis 2015;Suppl 1:S392-3
71. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008;117:244-79
72. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57
73. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria t lymphocytes in Crohn's disease. Gut 2002;50:206-11
74. Van den Brande JM, Koehler TC, Zelinkova Z, et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 2007;56:509-17
75. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85
76. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94
77. Connor EM, Eppihimer MJ, Morise Z, Granger DN, Grisham MB. Expression of mucosal addressin cell adhesion molecule-1 [MAdCAM-1] in acute and chronic inflammation. J Leukoc Biol 1999;65:349-55
78. Kawachi S, Jennings S, Panes J, et al. Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. Am J Physiol Gastrointest Liver Physiol 2000;278:G734-43
79. Ando T, Jordan P, Wang Y, et al. MAdCAM-1 expression and regulation in murine colonic endothelial cells in vitro. Inflamm Bowel Dis 2005;11:258-64
80. Arihiro S, Ohtani H, Suzuki M, et al. Differential expression of mucosal addressin cell adhesion molecule-1 [MAdCAM-1] in ulcerative colitis and Crohn's disease. Pathol Int 2002;52:367-74
81. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997;151:97-110
82. Biancheri P, Di Sabatino A, Rovedatti L, et al. Effect of tumor necrosis factor-a blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease. Inflamm Bowel Dis 2013;19:259-64
83. Wyant T, Estevam J, Yang L, Rosario M. Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab. Cytometry B Clin Cytom 2016;90:168-76
84. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: Results of the encore trial. Gastroenterology 2007;132:1672-83
85. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2016. doi: 10.1136/gutjnl-2015-311079. [Epub ahead of print.]